Study of 68Ga-NYM096 PETCT Imaging to Measure Tracer Uptake in Different Types of Cancer Including Primary and Metastatic Tumors

What this Trial Is About

Researchers are evaluating the uptake characteristics of 68Ga-NYM096 PETCT imaging in various types of tumors, including both primary and metastatic cancer lesions. This prospective, single-center study aims to provide important insights into how different tumors take up this imaging tracer, helping to identify the most promising uses of 68Ga-NYM096 PETCT for future cancer diagnosis and treatment assessment. Participants will receive a single intravenous dose of 68Ga-NYM096, with the amount adjusted based on body weight. After injection, a whole-body PETCT scan will be performed approximately 45 to 75 minutes later to capture detailed images of tumor uptake. The study focuses on quantitative analysis of tracer uptake in cancer lesions, measuring factors such as lesion number, maximum standardized uptake value SUVmax, and tumor-to-background ratio. During the study, participants will undergo the PETCT imaging procedure and provide informed consent. Researchers will analyze the images to assess tracer uptake characteristics in confirmed tumors. Safety and compliance with study procedures will be monitored. The main outcome is the quantitative assessment of tumor lesions on the 68Ga-NYM096 PETCT scan, evaluated from study completion to one month after. The study plans to enroll 120 patients with confirmed cancer diagnoses and will follow ethical guidelines throughout the research.

68Ga-NYM096 PET/CT in Various Kinds of Cancer